Clinical Trial Update: SKIPPAIN - Speed of Onset of SecuKinumab-Induced Relief From Pain in Patients With AxIal SpoNdyloarthritis [Phase 3]

View source ↗

Summary

Phase 3 trial update on SecuKinumab for speed of onset of relief in axial spondyloarthritis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spondyloarthritis

Drugs mentioned

• Secukinumab (secukinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Spondyloarthritis | Phase 3 | Status: COMPLETED | Results posted: 2020-02-19